noah rosen, md: evaluation of cardiovascular risks of galcanezumab in episodic, chronic migraine
Published 5 years ago • 539 plays • Length 2:20Download video MP4
Download video MP3
Similar videos
-
6:44
dosage and administration of the anti-cgrp monoclonal antibodies for migraine
-
1:18
regain trial of galcanezumab in chronic migraine
-
2:51
joshua cohen, md: fremanezumab’s impact on quality of life and comorbidities
-
4:39
administration and dosage of cgrp monoclonal antibodies
-
1:32
peter goadbsy, md, phd, dsc: differentiating between cgrps, synthesizing the gepants
-
5:47
hans-christoph diener, ean 2020 – chronic migraine and medication-overuse headache – promise-2
-
2:11
current biologic understandings of migraine
-
7:36
unprecedented efficacy of cgrp inhibitors for migraine
-
1:34
joshua cohen, md: fremanezumab for medication overuse headache
-
3:13
blame migraines on your parents
-
6:15
safety of cgrp inhibitors for migraine
-
4:24
christopher gottschalk, md: advantages of eptinezumab and cgrp inhibitors
-
2:44
promise-1: eptinezumab in episodic migraine
-
3:19
migraine headaches—advances in treatment
-
12:26
what's new in migraine
-
6:28
the neurobiology of chronic migraine
-
3:30
migraine: a neurological condition that's not just in your head
-
1:52
migraine infarction
-
4:34
what you need to know about acute & preventive migraine treatments - explainer video series